ROCKVILLE, Md., April 16 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD - News), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced the presentation of results for its preclinical tubulin inhibitor compounds. The data were presented by EntreMed scientists at the American Association for Cancer Research (AACR) Annual Meeting in Los Angeles, California.
